Faculty profile

Michael Houghton

ResearcherMedicineUniversity of Alberta

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses may be missing. Find their university profile.

Michael Houghton

Researcher

Medicine

Health Sciences

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
10 publications in the last five years, latest in 2026.
Principal investigator on 7 research grants (7 CIHR), most recently in 2023.
Supervised 6 trainees who won CIHR awards, most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Vaccine Neutralizing Antibody Hepatitis C Virus Candidate Therapeutic Candidate Vaccine Coronaviruses Covid19 Emerging Coronavirus

Latest papers

Virus-specific T cells and neutralizing antibodies are independent correlates of long-term protective immunity against hepatitis C virus.
Journal of virology · 2026
A rat hepacivirus model to aid hepatitis C viral vaccine development?
Journal of hepatology · 2025 · first author
Discovery of Novel Pyrido[2,3-b]Pyrazine Human Cytomegalovirus Polymerase Inhibitors with Broad Spectrum Antiherpetic Activity and Reduced hERG Inhibition.
ChemMedChem · 2025

All 58 publications

Latest funding

Disruption of the Rubicon/Rab7/VPS34 complex as a therapeutic strategy to activate autophagy in metabolic dysfunction-associated fatty liver disease
CIHR · 2025 · Supervisor
$140,000
Phase 1 randomized, double-blinded, placebo-controlled clinical trial of an adjuvanted protein-based Hepatitis C Virus (HCV) vaccine candidate
CIHR · 2023 · Principal investigator
$2,050,829
Phase 1 randomized, double-blinded, placebo-controlled clinical trial of an adjuvanted protein-based Hepatitis C Virus (HCV) vaccine candidate
CIHR · 2023 · Principal investigator
$512,707

All 16 grants and awards

58 publications.

Virus-specific T cells and neutralizing antibodies are independent correlates of long-term protective immunity against hepatitis C virus.

Gomez-Escobar E, Siddique A, Khedr O, Bédard N, Fieffé-Bédard A, Abdeltawab NF, Flores N, Abdel-Hakeem MS, Eisa M, Zang G, Law JLM, Kundu J, Houghton M, Bruneau J, Shoukry NH

Journal of virology2026

DOI: 10.1128/jvi.00849-26 PMID: 42720294

A rat hepacivirus model to aid hepatitis C viral vaccine development?

Houghton M

Journal of hepatology2025First author

DOI: 10.1016/j.jhep.2025.04.016 PMID: 40250765

Discovery of Novel Pyrido[2,3-b]Pyrazine Human Cytomegalovirus Polymerase Inhibitors with Broad Spectrum Antiherpetic Activity and Reduced hERG Inhibition.

Bai B, Srinivas Kandadai A, Hena M, Belovodskiy A, Shen J, Houghton M, Nieman JA

ChemMedChem2025

DOI: 10.1002/cmdc.202400629 PMID: 39656778

Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.

Kundu J, Le HT, Logan M, Hockman D, Landi A, Crawford K, Wininger M, Johnson J, Kundu JK, Tiffney EA, Urbanowicz RA, Ball JK, Bailey JR, Bukh J, Law M, Foung S, Tyrrell DL, Houghton M, Law JL

Journal of hepatology2024

DOI: 10.1016/j.jhep.2024.06.029 PMID: 38986744

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

Meier-Stephenson V, Hawkes MT, Burton C, Calcutt A, Davis C, Dooley J, Good M, Houghton M, Keeffe E, Kim K, Lepletier A, O'Neil C, Ogbuehi I, Ozberk V, Pandey M, Reynolds S, Seth A, Stokes W, Tse-Chang A, Tyrrell B, Tyrrell DL, Tyrrell GJ, Yaskina M

Trials2024

DOI: 10.1186/s13063-024-08634-4 PMID: 39563457

Small molecules targeting GRP78 mitigate anti-GRP78 autoantibody–mediated tissue factor procoagulant activity in cultured endothelial cells

Chen J, Lynn EG, Sharma H, Byun JH, Kenyon VA, Sahu KK, Tyrrell DL, Houghton M, Gross PL, Trigatti BL

Journal of Thrombosis and Haemostasis20243 citations

DOI: 10.1016/j.jtha.2024.07.015

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model.

Liang TJ, Law JLM, Pietschmann T, Ray SC, Bukh J, Bull R, Chung RT, Tyrrell DL, Houghton M, Rice CM

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

DOI: 10.1093/cid/ciad336 PMID: 37579208

Bovine Serum Albumin-Protected Gold Nanoclusters for Sensing of SARS-CoV-2 Antibodies and Virus.

Shen Q, Hossain F, Fang C, Shu T, Zhang X, Law JLM, Logan M, Houghton M, Tyrrell DL, Joyce MA, Serpe MJ

ACS applied materials & interfaces2023

DOI: 10.1021/acsami.3c03705 PMID: 37314985

Utilization of a Glucometer Test Strip and Enzymatic Reactions to Quantify Anti-SARS-CoV-2 Spike RBD IgG Antibody and SARS-CoV-2 Virus in Saliva and Serum.

Hossain F, Shen Q, Balasuriya N, Law JLM, Logan M, Houghton M, Tyrrell DL, Joyce MA, Serpe MJ

Analytical chemistry2023

DOI: 10.1021/acs.analchem.3c00481 PMID: 37150898

Three-Dimensional Reconstruction of the Hepatitis C Virus Envelope Glycoprotein E1E2 Heterodimer by Electron Microscopic Analysis.

Kanai T, Hu Z, Yang R, Wu W, Wang Z, Ma CD, Sanchez-Meza J, Law M, Houghton M, Law JL, Logan M, de Val N, Liang TJ

Journal of virology2023

DOI: 10.1128/jvi.01788-22 PMID: 36519897

Something wrong or missing on this profile? Suggest a correction

Michael Houghton

Research

Latest papers

Latest funding

Virus-specific T cells and neutralizing antibodies are independent correlates of long-term protective immunity against hepatitis C virus.

A rat hepacivirus model to aid hepatitis C viral vaccine development?

Discovery of Novel Pyrido[2,3-b]Pyrazine Human Cytomegalovirus Polymerase Inhibitors with Broad Spectrum Antiherpetic Activity and Reduced hERG Inhibition.

Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

Small molecules targeting GRP78 mitigate anti-GRP78 autoantibody–mediated tissue factor procoagulant activity in cultured endothelial cells

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model.

Bovine Serum Albumin-Protected Gold Nanoclusters for Sensing of SARS-CoV-2 Antibodies and Virus.

Utilization of a Glucometer Test Strip and Enzymatic Reactions to Quantify Anti-SARS-CoV-2 Spike RBD IgG Antibody and SARS-CoV-2 Virus in Saliva and Serum.

Three-Dimensional Reconstruction of the Hepatitis C Virus Envelope Glycoprotein E1E2 Heterodimer by Electron Microscopic Analysis.

Atomistic Computational Models To Evaluate Protein-Ligand Off-Target Interactions

Frequent collaborators

Khaled Barakat

Atul Humar

Jack Tuszynski

Deepali Kumar

Shokrollah Elahi

Matthew Croxen

Vanessa Meier-Stephenson

Maryna Yaskina

Lakshmi Krishnan

Bobby Shayegan

Peter Lawrence Gross

Richard Lehner

Bernardo Trigatti

David Proud

Matthias Götte

David Broadhurst

Richard C Austin